Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Ginkgo Bioworks Holdings, the most common co-covered peer. The tracked stories average 2 original sources each. Ginkgo Bioworks appears in 1 tracked Biotech story from February 27, 2026.
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Ginkgo Bioworks Holdings, the most common co-covered peer. The tracked stories average 2 original sources each. Ginkgo Bioworks appears in 1 tracked Biotech story from February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ginkgo Bioworks. Shared-story counts are live from our verified record — not editorial picks.
Ginkgo Bioworks (NYSE: DNA) reported a substantial earnings beat for the most recent quarter, outperforming analyst expectations by $0.38 per share. This performance highlights the company's progress in scaling its cell programming platform and optimizing its cost structure amidst a challenging environment for synthetic biology firms.
Source: themarketsdaily.com · benzinga.com
Ginkgo Bioworks is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
